File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Comparison of two dosages of recombinant human follicle-stimulating hormone in Chinese women undergoing controlled ovarian stimulation: Prospective randomised double-blind study

TitleComparison of two dosages of recombinant human follicle-stimulating hormone in Chinese women undergoing controlled ovarian stimulation: Prospective randomised double-blind study
Authors
KeywordsFertilization in vitro
FSH/administration & dosage
Ovulation induction
Pregnancy rate
Recombinant proteins/administration & dosage
Issue Date2000
PublisherHong Kong Medical Association. The Journal's web site is located at http://www.hkmj.org/resources/supp.html
Citation
Hong Kong Medical Journal, 2000, v. 6 n. 4, p. 368-374 How to Cite?
AbstractObjective: To compare two dosages of recombinant human follicle-stimulating hormone for controlled ovarian stimulation. Design: Prospective, randomised double-blind study. Setting: Tertiary assisted reproduction unit, Hong Kong. Participants: Forty subfertile Chinese women aged 24 to 38 years undergoing in vitro fertilisation. Entry criteria included good physical and mental health, and a body mass index between 18 and 29 kg/m2. Exclusion criteria were subfertility caused by an endocrine abnormality, polycystic ovarian syndrome, or absent ovarian function; previous assisted reproduction treatment in which fewer than three oocytes were retrieved; prior hospitalisation due to severe ovarian hyperstimulation syndrome; chronic cardiovascular, hepatic, renal, or pulmonary disease; alcohol or drug abuse; and the administration of investigational drugs within the previous 3 months. Intervention: Injection of recombinant follicle-stimulating hormone, 100 IU/d or 200 IU/d. Main outcome measures: The number of oocytes, total dose of drug used, and pregnancy rates. Results: Compared with the 20 women receiving 200 IU/d, the 20 who received 100 IU/d had a significantly lower median number of oocytes retrieved and median total dose of drug used (7.5 versus 15.0 [P<0.001] and 1200 IU versus 2000 IU [P<0.001], respectively). The pregnancy rates in the fresh cycles were similar (20%) in both groups, but the cumulative pregnancy rates in the 100 IU/d and 200 IU/d groups were 20.0% and 45.0% per stimulated cycle, respectively. The incidence of ovarian hyperstimulation syndrome in the 100 IU/d and 200 IU/d groups was 5.0% and 20.0%, respectively. Conclusions: Use of 100 IU/d of recombinant follicle-stimulating hormone requires a lower total dose but results in the harvest of half the number of oocytes compared with when a dosage of 200 IU/d is used.
Persistent Identifierhttp://hdl.handle.net/10722/53576
ISSN
2015 Impact Factor: 0.887
2015 SCImago Journal Rankings: 0.279
References

 

DC FieldValueLanguage
dc.contributor.authorNg, EHYen_HK
dc.contributor.authorYeung, WSBen_HK
dc.contributor.authorHo, PCen_HK
dc.date.accessioned2009-04-03T07:23:36Z-
dc.date.available2009-04-03T07:23:36Z-
dc.date.issued2000en_HK
dc.identifier.citationHong Kong Medical Journal, 2000, v. 6 n. 4, p. 368-374en_HK
dc.identifier.issn1024-2708en_HK
dc.identifier.urihttp://hdl.handle.net/10722/53576-
dc.description.abstractObjective: To compare two dosages of recombinant human follicle-stimulating hormone for controlled ovarian stimulation. Design: Prospective, randomised double-blind study. Setting: Tertiary assisted reproduction unit, Hong Kong. Participants: Forty subfertile Chinese women aged 24 to 38 years undergoing in vitro fertilisation. Entry criteria included good physical and mental health, and a body mass index between 18 and 29 kg/m2. Exclusion criteria were subfertility caused by an endocrine abnormality, polycystic ovarian syndrome, or absent ovarian function; previous assisted reproduction treatment in which fewer than three oocytes were retrieved; prior hospitalisation due to severe ovarian hyperstimulation syndrome; chronic cardiovascular, hepatic, renal, or pulmonary disease; alcohol or drug abuse; and the administration of investigational drugs within the previous 3 months. Intervention: Injection of recombinant follicle-stimulating hormone, 100 IU/d or 200 IU/d. Main outcome measures: The number of oocytes, total dose of drug used, and pregnancy rates. Results: Compared with the 20 women receiving 200 IU/d, the 20 who received 100 IU/d had a significantly lower median number of oocytes retrieved and median total dose of drug used (7.5 versus 15.0 [P<0.001] and 1200 IU versus 2000 IU [P<0.001], respectively). The pregnancy rates in the fresh cycles were similar (20%) in both groups, but the cumulative pregnancy rates in the 100 IU/d and 200 IU/d groups were 20.0% and 45.0% per stimulated cycle, respectively. The incidence of ovarian hyperstimulation syndrome in the 100 IU/d and 200 IU/d groups was 5.0% and 20.0%, respectively. Conclusions: Use of 100 IU/d of recombinant follicle-stimulating hormone requires a lower total dose but results in the harvest of half the number of oocytes compared with when a dosage of 200 IU/d is used.en_HK
dc.languageengen_HK
dc.publisherHong Kong Medical Association. The Journal's web site is located at http://www.hkmj.org/resources/supp.htmlen_HK
dc.relation.ispartofHong Kong Medical Journalen_HK
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License-
dc.rightsHong Kong Medical Journal. Copyright © Hong Kong Medical Association.en_HK
dc.subjectFertilization in vitroen_HK
dc.subjectFSH/administration & dosageen_HK
dc.subjectOvulation inductionen_HK
dc.subjectPregnancy rateen_HK
dc.subjectRecombinant proteins/administration & dosageen_HK
dc.subject.meshFollicle Stimulating Hormone - administration & dosage - adverse effectsen_HK
dc.subject.meshOvulation Induction - methodsen_HK
dc.subject.meshBody Mass Indexen_HK
dc.subject.meshFertilization in Vitro - methodsen_HK
dc.subject.meshRecombinant Proteins - administration & dosage - adverse effectsen_HK
dc.titleComparison of two dosages of recombinant human follicle-stimulating hormone in Chinese women undergoing controlled ovarian stimulation: Prospective randomised double-blind studyen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1024-2708&volume=6&issue=4&spage=368&epage=374&date=2000&atitle=Comparison+of+two+dosages+of+recombinant+human+follicle-stimulating+hormone+in+Chinese+women+undergoing+controlled+ovarian+stimulation:+prospective+randomised+double-blind+studyen_HK
dc.identifier.emailNg, EHY:nghye@hkucc.hku.hken_HK
dc.identifier.emailYeung, WSB:wsbyeung@hkucc.hku.hken_HK
dc.identifier.emailHo, PC:pcho@hku.hken_HK
dc.identifier.authorityNg, EHY=rp00426en_HK
dc.identifier.authorityYeung, WSB=rp00331en_HK
dc.identifier.authorityHo, PC=rp00325en_HK
dc.description.naturepublished_or_final_versionen_HK
dc.identifier.pmid11177158-
dc.identifier.scopuseid_2-s2.0-0034475161en_HK
dc.identifier.hkuros56499-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0034475161&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume6en_HK
dc.identifier.issue4en_HK
dc.identifier.spage368en_HK
dc.identifier.epage374en_HK
dc.publisher.placeHong Kongen_HK
dc.identifier.scopusauthoridNg, EHY=35238184300en_HK
dc.identifier.scopusauthoridYeung, WSB=7102370745en_HK
dc.identifier.scopusauthoridHo, PC=7402211440en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats